Cargando…

Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity

Hypertrophic cardiomyopathy (HCM) has been considered the most common cause of sudden death (SD) in the young. However, introduction of implantable cardioverter-defibrillators (ICDs) in HCM has proved highly effective and the mainstay of preventing SD in children, adolescents, and adults by terminat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonaventura, Jiri, Maron, Barry J., Berul, Charles I., Rowin, Ethan J., Maron, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461211/
https://www.ncbi.nlm.nih.gov/pubmed/37645261
http://dx.doi.org/10.1016/j.hroo.2023.06.007
_version_ 1785097808088399872
author Bonaventura, Jiri
Maron, Barry J.
Berul, Charles I.
Rowin, Ethan J.
Maron, Martin S.
author_facet Bonaventura, Jiri
Maron, Barry J.
Berul, Charles I.
Rowin, Ethan J.
Maron, Martin S.
author_sort Bonaventura, Jiri
collection PubMed
description Hypertrophic cardiomyopathy (HCM) has been considered the most common cause of sudden death (SD) in the young. However, introduction of implantable cardioverter-defibrillators (ICDs) in HCM has proved highly effective and the mainstay of preventing SD in children, adolescents, and adults by terminating malignant ventricular tachyarrhythmias. Nevertheless, ICD decision making is generally regarded as more difficult in pediatrics, and the strategy for selecting ICD patients from this population remains without consensus. Prospective studies in HCM children and adolescents have shown the American Heart Association/American College of Cardiology traditional major risk marker strategy to be reliable with >90% sensitivity in selecting patients for SD prevention. International data in >2000 young HCM patients assembled over 20 years who were stratified by major risk markers showed ICDs effectively prevented SD in 20%. Alternatively, novel quantitative risk scoring initiatives provide 5-year risk estimates that are potentially useful as adjunctive tools to facilitate discussion of prophylactic ICD risks vs benefit but are as yet unsupported by prospective outcome studies. Risk scoring strategies are characterized by reasonable discriminatory statistical power (C-statistic 0.69-0.76) for identifying patients with SD events but with relatively low sensitivity, albeit with specificity comparable with the risk marker strategy. While some reticence for obligating healthy-appearing young patients to lifelong device implants is understandable, underutilization of the ICD in high-risk children and adolescents can represent a lost opportunity for fulfilling the long-standing aspiration of SD prevention. This review provides a critical assessment of the current strengths and weaknesses of SD risk stratification strategies in young HCM patients in an effort to clarify clinical decision making in this challenging subpopulation.
format Online
Article
Text
id pubmed-10461211
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104612112023-08-29 Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity Bonaventura, Jiri Maron, Barry J. Berul, Charles I. Rowin, Ethan J. Maron, Martin S. Heart Rhythm O2 Topics in Review Hypertrophic cardiomyopathy (HCM) has been considered the most common cause of sudden death (SD) in the young. However, introduction of implantable cardioverter-defibrillators (ICDs) in HCM has proved highly effective and the mainstay of preventing SD in children, adolescents, and adults by terminating malignant ventricular tachyarrhythmias. Nevertheless, ICD decision making is generally regarded as more difficult in pediatrics, and the strategy for selecting ICD patients from this population remains without consensus. Prospective studies in HCM children and adolescents have shown the American Heart Association/American College of Cardiology traditional major risk marker strategy to be reliable with >90% sensitivity in selecting patients for SD prevention. International data in >2000 young HCM patients assembled over 20 years who were stratified by major risk markers showed ICDs effectively prevented SD in 20%. Alternatively, novel quantitative risk scoring initiatives provide 5-year risk estimates that are potentially useful as adjunctive tools to facilitate discussion of prophylactic ICD risks vs benefit but are as yet unsupported by prospective outcome studies. Risk scoring strategies are characterized by reasonable discriminatory statistical power (C-statistic 0.69-0.76) for identifying patients with SD events but with relatively low sensitivity, albeit with specificity comparable with the risk marker strategy. While some reticence for obligating healthy-appearing young patients to lifelong device implants is understandable, underutilization of the ICD in high-risk children and adolescents can represent a lost opportunity for fulfilling the long-standing aspiration of SD prevention. This review provides a critical assessment of the current strengths and weaknesses of SD risk stratification strategies in young HCM patients in an effort to clarify clinical decision making in this challenging subpopulation. Elsevier 2023-06-20 /pmc/articles/PMC10461211/ /pubmed/37645261 http://dx.doi.org/10.1016/j.hroo.2023.06.007 Text en © 2023 Heart Rhythm Society. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Topics in Review
Bonaventura, Jiri
Maron, Barry J.
Berul, Charles I.
Rowin, Ethan J.
Maron, Martin S.
Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity
title Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity
title_full Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity
title_fullStr Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity
title_full_unstemmed Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity
title_short Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity
title_sort analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: dilemmas and clarity
topic Topics in Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461211/
https://www.ncbi.nlm.nih.gov/pubmed/37645261
http://dx.doi.org/10.1016/j.hroo.2023.06.007
work_keys_str_mv AT bonaventurajiri analysisofriskstratificationandpreventionofsuddendeathinpediatricpatientswithhypertrophiccardiomyopathydilemmasandclarity
AT maronbarryj analysisofriskstratificationandpreventionofsuddendeathinpediatricpatientswithhypertrophiccardiomyopathydilemmasandclarity
AT berulcharlesi analysisofriskstratificationandpreventionofsuddendeathinpediatricpatientswithhypertrophiccardiomyopathydilemmasandclarity
AT rowinethanj analysisofriskstratificationandpreventionofsuddendeathinpediatricpatientswithhypertrophiccardiomyopathydilemmasandclarity
AT maronmartins analysisofriskstratificationandpreventionofsuddendeathinpediatricpatientswithhypertrophiccardiomyopathydilemmasandclarity